<DOC>
	<DOCNO>NCT01521897</DOCNO>
	<brief_summary>This surveillance aim figure 1 ) use-results , 2 ) occurrence adverse event , 3 ) factor affect safety term safety infant start receive Prevenar age 2 less 7 month routine medical practice . This surveillance specifically focus occurrence following : 1 . Local reaction injection site 2 . Systemic reaction concomitant vaccine ( especially fever 39CÂ° )</brief_summary>
	<brief_title>Prevenar Special Use-result Surveillance Japan ( Regulatory PostMarketing Commitment Plan )</brief_title>
	<detailed_description>This surveillance conduct use continuous surveillance system , physician enroll patient meet enrollment criterion continuously contract sample size reach .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants age 2 less 7 month Infants vaccinate Prevenar first time Infants expect complete four vaccination Prevenar Vaccination Prevenar must give follow ; History evident anaphylactic reaction component Prevenar diphtheria toxoid Evident pyrexia Evident serious acute disease Any infants child ineligible vaccination</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pneumococcal Vaccine</keyword>
	<keyword>Prevenar</keyword>
	<keyword>7-valent</keyword>
	<keyword>Special Use-result surveillance</keyword>
</DOC>